NCT04491942
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients with progressing brain metastasis or leptomeningeal disease that requires treatment- see trial for details
https://ClinicalTrials.gov/show/NCT04491942